Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director · Chief Executive Officer | May 29, 2019 | May 31, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date May 29, 2019 · Filed May 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 290,687 |
Last balance in matching sequence
After 2019-05-30 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2019-05-29 · Sale · Disposed 2,200 · Balance 294,337 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 2 · 2019-05-29 · Sale · Disposed 725 · Balance 293,612 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 3 · 2019-05-30 · Sale · Disposed 1,425 · Balance 292,187 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 4 · 2019-05-30 · Sale · Disposed 1,500 · Balance 290,687 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 332,243 |
Reported balance
Holding disclosure · report date 2019-05-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 332,243 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2018 Filed Jan 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,100 | $35.46 | $39,006.00 |
DisclosureSEC source: 0001209191-18-005936 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 299,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.825 to $35.80 The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 200 | $34.68 | $6,936.00 |
DisclosureSEC source: 0001209191-18-005936 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 300,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,400 | $34.23 | $287,532.00 |
DisclosureSEC source: 0001209191-18-005936 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 301,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.65 to $34.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,400 | $33.22 | $46,508.00 |
DisclosureSEC source: 0001209191-18-005936 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 309,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $32.60 to $33.60. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 24, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $34.99 | $76,978.00 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 10 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F12 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.825 to $35.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 24, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,100 | $34.40 | $141,040.00 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 9 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F11 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.80 to $34.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 24, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,100 | $33.20 | $268,920.00 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 8 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F10 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $32.75 to $33.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 23, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,516 | $36.15 | $307,853.40 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 7 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F9 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.775 to $36.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 23, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 15,084 | $35.45 | $534,727.80 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 6 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,894 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F8 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.75 to $35.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 23, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 500 | $34.05 | $17,025.00 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F7 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.70 to $34.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,000 | $34.04 | $68,080.00 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 349,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.675 to $34.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,500 | $33.08 | $215,020.00 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 351,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $32.65 to $33.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,000 | $32.17 | $32,170.00 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 357,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $31.60 to $32.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 19:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 500 | $30.93 | $15,465.00 |
DisclosureSEC source: 0001209191-18-005277 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 358,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $30.45 to $31.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 17:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 600 | $30.38 | $18,228.00 |
DisclosureSEC source: 0001209191-18-004338 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 359,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $30.20 to $30.60. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 19:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 100 | $30.05 | $3,005.00 |
DisclosureSEC source: 0001209191-18-003484 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 360,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 19:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 17,500 | $22.01 | $385,175.00 |
DisclosureSEC source: 0001209191-18-003484 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 360,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $21.925 to $22.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 19:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $21.49 | $53,725.00 |
DisclosureSEC source: 0001209191-18-003484 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 377,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.90 to $21.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 19:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,100 | $20.38 | $83,558.00 |
DisclosureSEC source: 0001209191-18-003484 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 380,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.175 to $20.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 19:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,500 | $19.64 | $88,380.00 |
DisclosureSEC source: 0001209191-18-003484 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 384,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.15 to $20.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 19:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,700 | $20.28 | $54,756.00 |
DisclosureSEC source: 0001209191-18-000375 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 388,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 19:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,900 | $19.04 | $55,216.00 |
DisclosureSEC source: 0001209191-18-000375 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 391,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.675 to $19.475. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 19:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 14,400 | $18.24 | $262,656.00 |
DisclosureSEC source: 0001209191-18-000375 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 394,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.65 to $18.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 19:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $15.15 | $33,330.00 |
DisclosureSEC source: 0001209191-18-000375 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 408,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.90 to $15.275. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 17:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $14.73 | $32,406.00 |
DisclosureSEC source: 0001209191-17-065719 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 410,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.50 to $15.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 17:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $14.56 | $32,032.00 |
DisclosureSEC source: 0001209191-17-065719 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 413,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.50 to $14.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 16:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $14.40 | $31,680.00 |
DisclosureSEC source: 0001209191-17-063218 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 415,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.20 to $14.60. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 16:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $14.09 | $30,998.00 |
DisclosureSEC source: 0001209191-17-063218 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 417,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.80 to $14.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 18:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 5,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061607 · doc4.xml · derivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,938 Underlying: Common Stock · 5,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 18:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061607 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| November 14, 2017 Filed Nov 14, 2017 20:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $13.41 | $29,502.00 |
DisclosureSEC source: 0001209191-17-060763 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 419,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.20 to $13.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 20:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $13.53 | $29,766.00 |
DisclosureSEC source: 0001209191-17-060763 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 421,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.40 to $13.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 27, 2017 Filed Oct 30, 2017 16:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $13.60 | $29,920.00 |
DisclosureSEC source: 0001209191-17-058292 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 424,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.45 to $13.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 16:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $13.57 | $29,854.00 |
DisclosureSEC source: 0001209191-17-058292 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 426,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.35 to $13.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 12, 2017 Filed Oct 12, 2017 19:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $14.78 | $32,516.00 |
DisclosureSEC source: 0001209191-17-056781 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 428,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.65 to $15.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 11, 2017 Filed Oct 12, 2017 19:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $15.25 | $33,550.00 |
DisclosureSEC source: 0001209191-17-056781 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 430,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.10 to $15.475. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 20, 2017 Filed Sep 21, 2017 16:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $15.56 | $34,232.00 |
DisclosureSEC source: 0001209191-17-053590 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 432,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.25 to $15.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 16:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $15.51 | $34,122.00 |
DisclosureSEC source: 0001209191-17-053590 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 435,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.40 to $15.625. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 16:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $14.98 | $32,956.00 |
DisclosureSEC source: 0001209191-17-052034 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 437,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.75 to $15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 16:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $15.05 | $33,110.00 |
DisclosureSEC source: 0001209191-17-052034 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 439,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.85 to $15.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 17:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $13.51 | $29,722.00 |
DisclosureSEC source: 0001209191-17-050166 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 441,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.40 to $13.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| August 22, 2017 Filed Aug 24, 2017 17:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $13.56 | $29,832.00 |
DisclosureSEC source: 0001209191-17-050166 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 443,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.40 to $13.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 5,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049446 · doc4.xml · derivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,846 Underlying: Common Stock · 5,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049446 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 19:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $14.58 | $32,076.00 |
DisclosureSEC source: 0001209191-17-048820 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 446,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.40 to $14.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 19:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $14.75 | $32,450.00 |
DisclosureSEC source: 0001209191-17-048820 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 448,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.45 to $15.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 200 | $16.79 | $3,358.00 |
DisclosureSEC source: 0001209191-17-046332 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 450,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.70 to $16.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $15.97 | $39,925.00 |
DisclosureSEC source: 0001209191-17-046332 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 450,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.70 to $16.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 16:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $17.32 | $5,196.00 |
DisclosureSEC source: 0001209191-17-046332 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 453,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.30 to $17.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 16:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $16.89 | $42,225.00 |
DisclosureSEC source: 0001209191-17-046332 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 453,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.30 to $17.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.